全文获取类型
收费全文 | 1286篇 |
免费 | 91篇 |
国内免费 | 96篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 15篇 |
妇产科学 | 4篇 |
基础医学 | 185篇 |
口腔科学 | 10篇 |
临床医学 | 189篇 |
内科学 | 236篇 |
皮肤病学 | 36篇 |
神经病学 | 169篇 |
特种医学 | 138篇 |
外科学 | 166篇 |
综合类 | 38篇 |
一般理论 | 3篇 |
预防医学 | 69篇 |
眼科学 | 9篇 |
药学 | 143篇 |
中国医学 | 1篇 |
肿瘤学 | 61篇 |
出版年
2022年 | 6篇 |
2021年 | 21篇 |
2020年 | 13篇 |
2019年 | 22篇 |
2018年 | 25篇 |
2017年 | 21篇 |
2016年 | 17篇 |
2015年 | 28篇 |
2014年 | 35篇 |
2013年 | 64篇 |
2012年 | 54篇 |
2011年 | 76篇 |
2010年 | 53篇 |
2009年 | 55篇 |
2008年 | 71篇 |
2007年 | 127篇 |
2006年 | 62篇 |
2005年 | 65篇 |
2004年 | 49篇 |
2003年 | 33篇 |
2002年 | 54篇 |
2001年 | 35篇 |
2000年 | 50篇 |
1999年 | 42篇 |
1998年 | 31篇 |
1997年 | 20篇 |
1996年 | 26篇 |
1995年 | 32篇 |
1994年 | 31篇 |
1993年 | 24篇 |
1992年 | 26篇 |
1991年 | 16篇 |
1990年 | 26篇 |
1989年 | 24篇 |
1988年 | 20篇 |
1987年 | 17篇 |
1986年 | 14篇 |
1985年 | 12篇 |
1984年 | 14篇 |
1983年 | 9篇 |
1982年 | 5篇 |
1981年 | 3篇 |
1980年 | 5篇 |
1979年 | 5篇 |
1978年 | 5篇 |
1976年 | 5篇 |
1971年 | 4篇 |
1970年 | 4篇 |
1967年 | 4篇 |
1966年 | 3篇 |
排序方式: 共有1473条查询结果,搜索用时 187 毫秒
21.
Beaulieu E Kachra Z Mousseau N Delbecchi L Hardy J Béliveau R 《Neurosurgery》1999,45(6):1432-40; discussion 1440-1
22.
23.
Treatment of mild hyperhomocysteinemia in renal transplant recipients versus hemodialysis patients 总被引:3,自引:0,他引:3
Bostom AG Shemin D Gohh RY Beaulieu AJ Jacques PF Dworkin L Selhub J 《Transplantation》2000,69(10):2128-2131
BACKGROUND: Mild hyperhomocysteinemia is common among maintenance hemodialysis (HD) patients and renal transplant recipients (RTR) and may contribute to the excess incidence of arteriosclerotic outcomes experienced by both patient groups. Relative to their RTR counterparts, the hyperhomocysteinemia of HD patients seems to be considerably more refractory to treatment with high-dose folic acid (FA)-based B-vitamin supplementation regimens, although controlled comparison data are lacking. METHODS: We compared the relative responsiveness of (n=10) RTR and (n=39) HD patients with equivalent baseline total homocysteine (tHcy) levels (i.e., RTR range=14.2-23.6 micromol/L; HD range=14.4-24.9 micromol/L) to 12 weeks of tHcy-lowering treatment. The RTR received 2.4 mg/day of FA, 50.0 mg/day of vitamin B6, and 0.4 mg/day of vitamin B12, while the HD patients received 15 mg/day of FA or an equimolar amount (17 mg/day) of the reduced folate, L-5-methyltetrahydrofolate, in addition to 50.0 mg/day of vitamin B6, and 1.0 mg/day of vitamin B12. RESULTS: The mean percent (%) reductions (+/-95% confidence interval) in tHcy were: RTR=28.1% (16.2-40.0%); HD=12.1% (6.6-17.7%), P=0.027 for comparison of between-groups differences by analysis of covariance adjusted for baseline tHcy levels. Moreover, (50.0%) of 10 of the RTR versus only (5.1%) of 39 of the HD patients had final on-treatment tHcy levels <12 micromol/L; P=0.002 for comparison of between-groups differences by Fisher's exact test. CONCLUSION: Relative to RTR with comparable baseline tHcy levels, the mild hyperhomocysteinemia of maintenance HD patients is much more refractory to tHcy-lowering B-vitamin treatment regimens featuring supraphysiological amounts of FA or the reduced folate, L-5-methyltetrahydrofolate. Accordingly, RTR are a preferable target population for controlled clinical trials testing the hypothesis that tHcy-lowering B-vitamin intervention may reduce arteriosclerotic cardiovascular disease event rates in patients with chronic renal disease. 相似文献
24.
Han JY; Kim HK; Choi BG; Moon H; Hong YS; Lee KS 《Japanese journal of clinical oncology》1998,28(12):749-753
BACKGROUND: Quality of life (QOL) assessment has emerged to measure and
quantify the balance between treatment benefit and toxicity, and has a
value in predicting response and overall survival in cancer patients.
METHODS: From July 1995 to February 1997, 38 symptomatic patients with
advanced non-small cell lung cancer (NSCLC) were treated with MIP
chemotherapy (mitomycin 6 mg/m2, ifosfamide 3000 mg/m2 and cisplatin 50
mg/m2 on day 1 every 3 weeks). Patients were assessed for QOL including
physical well-being, general symptoms and lung cancer-specific symptoms, as
well as objective response. RESULTS: The overall response rate was 38.9%
(14/36, all were partial response) and the median duration of response was
3.5 months [95% confidence interval (CI) 2.0-4.0]. The median duration of
overall survival was 7 months (95% CI 5.9-8.5). The overall improvement of
QOL was 58.3% with 21 patients feeling better on treatment. The toxicity of
chemotherapy was mild, mainly nausea/vomiting and minimal alopecia. Using
multiple clinical predictors of survival (age, histology, stage,
performance status), only change of QOL emerged significantly (P = 0.0007).
CONCLUSIONS: MIP had an endurable response and low toxicity profile, and
provided good QOL. Integral QOL data in our study provided the strong
prediction of survival in advanced NSCLC. Further experienced QOL study
will provide greatly enhanced outcome data in clinical trials.
相似文献
25.
26.
27.
Yannick Beaus��jour Fernando Alvarez Martin Beaulieu Marc Bilodeau 《Journal canadien de gastroenterologie》2011,25(6):311-314
Benign recurrent intrahepatic cholestasis is a rare clinical entity that is caused by mutations in the canalicular transport genes. The present report describes two individuals from the same family whose symptoms were typical of the clinical characteristics of type 2 benign recurrent intrahepatic cholestasis. Sequencing of the ABCB11 gene revealed two previously unreported mutations that predict the absence of expression of the protein. The clinical presentation of the current cases are discussed, as are the differential diagnosis and genetic characteristics of the hereditary cholestatic disorders, overemphasizing the possibility of making a definite genetic diagnosis. 相似文献
28.
29.
Firoza Mamdani Marcelo T. Berlim Marie-Martine Beaulieu Gustavo Turecki 《The world journal of biological psychiatry》2014,15(2):135-144
Objectives. A significant proportion of patients with major depressive disorder (MDD) do not improve following treatment with first-line antidepressants and, currently, there are no objective indicators of predictors of antidepressant response. The aim of this study was to investigate pre-treatment peripheral gene expression differences between future remitters and non-responders to citalopram treatment and identify potential pharmacogenomic predictors of response. Methods. We conducted a gene expression study using Affymetrix HG-U133 Plus2 microarrays in peripheral blood samples from untreated individuals with MDD (N = 77), ascertained at a community outpatient clinic, prior to an 8-week treatment with citalopram. Gene expression differences were assessed between remitters and non-responders to treatment. Technical validation of significant probesets was carried out by qRT-PCR. Results. A total of 434 probesets displayed significant correlation to change in score and 33 probesests were differentially expressed between eventual remitters and non-responders. Probesets for SMAD 7 (SMA- and MAD-related protein 7) and SIGLECP3 (sialic acid-binding immunoglobulin-like lectin, pseudogene 3) were the most significant differentially expressed genes following FDR correction, and both were down-regulated in individuals who responded to treatment. Conclusions. These findings point to SMAD7 and SIGLECP3 as candidate predictive biomarkers of antidepressant response. 相似文献
30.